MOLBIO2026-04-012026-06-30MOLBIO2026-04-012026-06-30in-capmkt:OtherExpenses1MemberMOLBIO2026-04-012026-06-30

ItemsThatWillNotBeReclassifiedToProfitAndLoss1

iso4217:INRiso4217:INRxbrli:shares

544866

MOLBIO

NOTLISTED

INE869T01028

Molbio Diagnostics Limited

Main Board

Equity

2026-04-01

2027-03-31

2026-09-05

2026-09-01

INR

Millions

Quarterly

First quarter

Single segment

Healthcare

2026-09-05

11:47:00

2026-09-05

16:00:00

Not applicable

false

There is no Default on Loans and Debt Securities for the quarter ended June 30,2026.

2026-04-01

2026-06-30

Unaudited

Standalone

3993780000

13680000

4007460000

1267240000

60920000

114350000

247560000

86620000

84180000

1387350000

3248220000

759240000

221990000

-29020000

192970000

566270000

-630000

565640000

112760000

5.02

1. The Statement of unaudited standalone financial results for the quarter ended June 30, 2026 of Molbio Diagnostics Limited (formerly Molbio Diagnostics Private Limited) ("the Company") has been reviewed by the Audit Committee and recommended for approval to the Board of Directors of the Company and the Board of Directors approved the same at their meeting held on September 05, 2026. The statutory auditors have conducted a limited review of the above unaudited standalone financial results. 2. The Statement of unaudited standalone financial results for the quarter ended June 30, 2026 of the Company has been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with the relevant rules thereunder and in terms of Regulation 33 of the Securities and Exchange Board of India ('SEBI') (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 3. Subsequent to the quarter ended June 30, 2026, the Company has completed its Initial Public Offer (IPO) of 11,646,246 equity shares (includes employee reservation portion of 20,519 equity shares) of face value of Rs. 1 each at an issue price of Rs. 807 per equity share per share to investors other than employees and at an issue price of Rs. 731 per equity share to employees. The issue consisted of a fresh issue of 2,480,246 equity shares aggregating to Rs. 2,000.00 Million and an offer for sale of 9,166,000 equity shares by selling shareholders aggregating to Rs. 7,396.96 Million. The Company's equity shares were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on August 17, 2026. Accordingly, these financial results for the quarter ended 30 June 2026 have been drawn up for the first time in accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. 4. The shareholders of the Company through a special resolution at the extra-ordinary general meeting approved the ‘Employee Stock Option Plan 2025 (“ESOP 2025”/ “Plan”) for creation of ESOP pool of 2,819,000 options having face value of Rs. 1/- each fully paid up which constitutes 2.5% of the paid up share capital of the Company. However, no stock options have been granted as at June 30, 2026. Further, subsequent to quarter ended June 30, 2026, the Company has granted 854,480 options to the employees. 5. On November 21, 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws, collectively referred to as the 'New Labour Codes'. The Company has assessed and disclosed the incremental impact of these changes, which has resulted in increase in gratuity liability by Rs. 23.15 Million and increase in leave liability (compensated absences) by Rs. 8.19 Million. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company has presented this incremental amount as Exceptional Item in the Statement of Profit and Loss for the year ended March 31, 2026. The Company continues to monitor the developments pertaining to the implementation of the New Labour Codes, including related rules there to. 6. A survey under Section 133A of the Income-tax Act, 1961 (“IT Act”), was carried out at the premises of the Company, by the Income Tax authorities during the year ended March, 2024 for the AY 20-21 to AY 23-24, followed by search closure visits on various dates to check the compliance with the provisions of the IT Act. The income tax department has subsequently sought certain information/ clarifications, which have been submitted by the Company. The department has raised tax demands aggregating to Rs. 208.71 Million plus interest and penalty, as applicable, vide assessment / reassessment order for the AY 2020-21 to 2024-25. In response to the same, the Company has made appeal to the Commissioner Income Tax (Appeals) along with rectification applications. Management believes that the Company has complied with all the applicable provisions of the IT Act with respect to its operations. The Company has paid an amount of Rs. 78.95 Million as at June 30, 2026 in connection with the survey which has been classified under Non-current tax assets (net). The management of the Company is confident of favourable outcome and accordingly no adjustments have been made in the unaudited standalone financial results for the quarter ended June 30, 2026 in this regard. 7. a. During the year ended March 31, 2025, the Company, OptraSCAN, Inc. (“OptraSCAN”), its promoters and other existing shareholders entered into a Stock Purchase Agreement. Pursuant to the agreement, the Company subscribed to 2,918,827 Series B preferred shares (no par value), representing a 19.68% equity interest in OptraSCAN, for a consideration of Rs. 415.52 Million (USD 4.90 Million). Accordingly, OptraSCAN became an associate of the Company. Further, during the year ended March 31, 2026, the Company subscribed to an additional 14,951,540 Series B preferred shares (no par value) of OptraSCAN for a consideration of Rs.2,220.91 Million (USD 25.10 Million). Pursuant to this acquisition, effective November 01, 2025, the Company’s shareholding increased to 60%, resulting in OptraSCAN becoming a subsidiary of the Company. b. As at March 31, 2026, the Company held 890,103 Class A equity shares of Prognosys Medical Systems Private Limited ("PMS") (face value: Rs. 10 each), amounting to Rs. 144.60 Million, and 1,514,872 0.0001% compulsorily convertible preference shares of PMS (face value: Rs. 10 each), amounting to Rs. 246.11 Million, cumulatively representing a 65.47% shareholding in PMS. During the quarter ended June 30, 2026, the Company, PMS, the promoters and the other existing shareholders of PMS entered into a share purchase agreement (collectively referred to as the “PMS SPA”), pursuant to which the Company acquired an additional 146,817 Class A equity shares of PMS (face value: Rs. 10 each), representing 4.53% of the shareholding in PMS, from the existing shareholders for an aggregate cash consideration of Rs. 1.47 Million. Consequently, the Company’s cumulative shareholding in PMS increased from 65.47% to 70.00%. 8. The operating segment of the Company is identified to be "Healthcare", as the Chief Operating Decision Maker reviews business performance at an overall company level as one segment. Therefore, the disclosure as per Ind AS 108 "Operating segments" and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended is not applicable to the Company. 9. During the quarter ended September 30, 2025, the Company has allotted the bonus shares aggregating to 90,207,800 equity shares in accordance with Section 63 of the Act in the ratio of 4:1 i.e., 4 fully paid-up equity shares for every 1 equity share of face value of Rs. 1 each. In accordance with the provision of Ind AS 33, Basic and Diluted EPS for the quarter ended June 30, 2025 have been adjusted and presented. 10. The figures for the quarter ended March 31, 2026 represent the balancing figures between the audited figures for the financial year ended March 31, 2026 and the unaudited year-to-date figures up to December 31, 2025 compiled by management. Further, the figures for the quarter ended June 30, 2025 have been complied by management. Neither the figures for the quarter ended March 31, 2026 nor those for the quarter ended June 30, 2025 have been subjected to audit or review by the statutory auditors.

For the said quarter it is not applicable

Other Expenses

1387350000

Re-measurement gains / (losses) on defined benefit plan

-840000

-210000

-630000